OncoMatch/Clinical Trials/NCT03658785
Immunotherapy for the Treatment of Advanced Solid Tumor
Is NCT03658785 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including TIL and Aldesleukin for recurrence tumor.
Treatment: TIL · Aldesleukin · Cyclophosphamide · Fludarabine — The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes (TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any prior therapy directed at the malignant tumor
Patients must have progressive disease while receiving or after the completion of the most recent prior treatment
Cannot have received: organ allograft
Patients who have received an organ allograft
Cannot have received: prior cell transfer therapy
Patients who have received...prior cell transfer therapy
Lab requirements
Blood counts
ANC > 1000/mm³ without filgrastim; WBC ≥ 3000/mm³; platelets ≥ 100,000/mm³; hemoglobin > 8.0 g/dl
Kidney function
Serum creatinine ≤ 1.6 mg/dl
Liver function
Serum ALT/AST ≤ 2.5x ULN; total bilirubin ≤ 1.5 mg/dl (≤ 3.0 mg/dl for Gilbert's Syndrome)
Cardiac function
LVEF ≥ 45%; NYHA Class < 2
Hematology: ANC > 1000/mm(3) without filgrastim; WBC ≥ 3000/mm(3); Platelet count ≥ 100,000/mm(3); Hemoglobin > 8.0 g/dl. Chemistry: ALT/AST ≤ 2.5x ULN; creatinine ≤ 1.6 mg/dl; total bilirubin ≤ 1.5 mg/dl (≤ 3.0 mg/dl for Gilbert's Syndrome). Cardiac: LVEF < 45% or NYHA Class 2 or higher [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify